Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. reports developments as a life sciences and health-innovation platform with operating subsidiaries focused on diagnostics, precision oncology, and immune-system technologies. Company news includes updates on Ignite Proteomics, a commercial-stage precision oncology business that uses functional protein profiling to support cancer therapy selection, and Pearsanta, which is developing blood-based diagnostic tests including the Mitomic Endometriosis Test.
Recurring ADTX coverage also includes subsidiary leadership, clinical and research publications, acquisition activity, shareholder votes, reverse stock splits, Nasdaq listing matters, and other capital-structure actions tied to the company’s publicly traded common stock.
Aditxt (Nasdaq: ADTX) subsidiary Pearsanta began enrollment on October 27, 2025 in a prospective clinical study to evaluate the Mitomic® Endometriosis Test (MET™), a blood-based diagnostic for endometriosis.
The study will enroll up to 1,000 participants referred for diagnostic laparoscopy, collect pre-operative blood samples and symptom questionnaires, and compare MET™ performance to laparoscopic diagnosis. The first site, Dedicated to Women OB/GYN in Dover, DE, is now enrolling. The trial is registered as NCT06907550. Results are intended to support launch of MET™ as a Laboratory Developed Test (LDT) in Pearsanta’s CLIA/CAP laboratory in Richmond, Virginia.
Evofem Biosciences (OTCID: EVFM) announced on October 20, 2025 that its stockholders did not approve the Amended and Restated Merger Agreement with Aditxt (NASDAQ: ADTX), and Evofem has exercised its rights to terminate the Merger Agreement.
The company said it will pivot to regain a national listing for its stock and secure growth capital to catalyze net sales while targeting sustainable positive EBITDA in 2027. Evofem noted a continuing collaboration with Aditxt to commercialize Mitomic diagnostic tests under their September 2024 agreement.
Evofem commercializes two FDA-approved sexual health products, PHEXXI vaginal gel and SOLOSEC oral granules, and reported 2024 was its fourth consecutive year of net sales growth.
Evofem Biosciences (OTCID: EVFM) reported significant success from its August 2025 "Say Vagina" campaign, designed to normalize clinical anatomical language. The campaign generated over 2.5 million views across social media platforms and drove a 130% increase in traffic to PHEXXI.com, the company's hormone-free contraceptive product website.
Key achievements include PHEXXI becoming the #1 most followed contraceptive brand among healthcare providers, and CEO Saundra Pelletier's Instagram reach growing by 400%. The company plans to launch SayVaginaStore.com in September, with all proceeds from campaign merchandise being donated to selected sexual and reproductive health charities.
Evofem Biosciences (OTCID: EVFM) expects approval of its merger with Aditxt (Nasdaq: ADTX) at the upcoming Special Meeting of Stockholders on September 26, 2025. The company has secured support agreements from Series E-1 and G-1 holders, representing 53.71% of combined voting power, sufficient for merger approval.
Under the agreement, Evofem will become a wholly-owned subsidiary of Aditxt, forming the core of their women's health program. As of August 26, 2025, Evofem had 118,656,354 shares of common stock outstanding, with Series E-1 and G-1 holders controlling 13.87% and 39.84% of voting power, respectively.
Aditxt (NASDAQ:ADTX) announced updates on its subsidiary Adimune's DNA-based therapeutic platform for reprogramming the immune system. The company has secured a robust intellectual property portfolio of 96 granted and 22 pending patents targeting the autoimmune therapeutics market, projected to reach $160 billion by 2030.
Adimune's first product candidate, ADI-100, targets conditions including type 1 diabetes, psoriasis, and stiff person syndrome. The company plans to seek FDA submission and approval for first-in-human trials in early 2026. The platform aims to restore immune tolerance without chronic immunosuppression through DNA instructions and a proprietary delivery system.
Evofem Biosciences (OTCID: EVFM) announced that Illinois has passed House Bill 3489, allowing pharmacists to prescribe non-hormonal and emergency contraceptives, including PHEXXI®, effective January 1, 2026.
The legislation positions Illinois alongside 30 other states and DC in permitting pharmacist-prescribed contraceptives. PHEXXI, FDA-approved in May 2020, is a hormone-free vaginal gel contraceptive that can be used regardless of BMI and showed increased sexual satisfaction in clinical trials.
The law, introduced by Representative Michelle Mussman and sponsored by Senator Rachael Ventura, aims to expand contraceptive access and choices for Illinois residents.
Evofem Biosciences (OTCID: EVFM) announced that a new U.S. patent for SOLOSEC®, their single-dose oral treatment for bacterial vaginosis and trichomoniasis, has been listed in the FDA Orange Book. The newly listed patent (No. 12,280,037) covers the method, pharmaceutical composition, and use in treating trichomoniasis, extending market exclusivity until December 2041.
SOLOSEC is notable as the first and only FDA-approved single-dose oral treatment for both bacterial vaginosis and trichomoniasis. The company is currently conducting a Phase 4 clinical trial comparing SOLOSEC's effectiveness and cost-effectiveness against metronidazole in treating T. vaginalis infections, which affect an estimated 6.9 million new cases annually in the U.S.
Evofem Biosciences (OTCID: EVFM) reported improved financial results for Q2 2025, with net sales increasing 16% to $4.8 million compared to $4.2 million in Q2 2024. The company reduced its loss from operations to $1.3 million from $1.4 million year-over-year.
Key developments include advancing strategies to reduce manufacturing costs by 50% for PHEXXI and SOLOSEC, expanding into UAE markets, and progress in clinical trials. The company is proceeding with plans to become a wholly-owned subsidiary of Aditxt, having raised $2.4 million through senior subordinated notes and warrants in Q2 2025.
The company reported a net loss of $(0.02) per share compared to a net income of $0.02 per share in Q2 2024, with cash and equivalents of $0.7 million as of June 30, 2025.
Aditxt (Nasdaq: ADTX) has signed a custody agreement with Crypto.com to establish a custodial crypto account as part of its bitXbio™ initiative. The agreement positions Crypto.com as the custodian for Aditxt's proposed digital treasury, which plans to back biotech innovation with digital assets including Bitcoin.
Additionally, ADTX common stock is now available for trading through Crypto.com's broker-dealer, providing crypto-native retail and institutional investors easier access to ADTX shares. The partnership supports Aditxt's bitXbio™ platform, which focuses on expanding access to innovations in immune reprogramming, early cancer detection, and women's health.
Evofem Biosciences (OTCID: EVFM) announced that CEO Saundra Pelletier will receive the Trailblazing Female Founders Award at the 2025 STIMULATE Conference in Nashville. The recognition comes during Say Vagina Month, an initiative launched by Evofem to destigmatize vaginal health discussions.
The company highlighted clinical data showing that 90% of women using their hormone-free contraceptive PHEXXI® maintained or improved sexual satisfaction in the Phase 3 AMPOWER trial, as published in the Journal of Sexual Medicine. Evofem continues its mission of empowering women through science, advocacy, and access to healthcare.